Biomarkers

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 1096131 Experts worldwide ranked by ideXlab platform

C. A. Lacueva - One of the best experts on this subject based on the ideXlab platform.

  • Validation of Biomarkers of food intake¿critical assessment of candidate Biomarkers
    Genes and Nutrition, 2018
    Co-Authors: Laars Ove Dragsted, Augustin Scalbert, G. Vergeres, M. Kolehmainen, Claudine Manach, L. Brennan, L. A. Afman, D. S. Wishart, C. A. Lacueva
    Abstract:

    Biomarkers of food intake (BFIs) are a promising tool for limiting misclassification in nutrition research where more subjective dietary assessment instruments are used. They may also be used to assess compliance to dietary guidelines or to a dietary intervention. Biomarkers therefore hold promise for direct and objective measurement of food intake. However, the number of comprehensively validated Biomarkers of food intake is limited to just a few. Many new candidate Biomarkers emerge from metabolic profiling studies and from advances in food chemistry. Furthermore, candidate food intake Biomarkers may also be identified based on extensive literature reviews such as described in the guidelines for Biomarker of Food Intake Reviews (BFIRev). To systematically and critically assess the validity of candidate Biomarkers of food intake, it is necessary to outline and streamline an optimal and reproducible validation process. A consensus-based procedure was used to provide and evaluate a set of the most important criteria for systematic validation of BFIs. As a result, a validation procedure was developed including eight criteria, plausibility, dose-response, time-response, robustness, reliability, stability, analytical performance, and inter-laboratory reproducibility. The validation has a dual purpose: (1) to estimate the current level of validation of candidate Biomarkers of food intake based on an objective and systematic approach and (2) to pinpoint which additional studies are needed to provide full validation of each candidate biomarker of food intake. This position paper on biomarker of food intake validation outlines the second step of the BFIRev procedure but may also be used as such for validation of new candidate Biomarkers identified, e.g., in food metabolomic studies.

  • Validation of Biomarkers of food intake-critical assessment of candidate Biomarkers
    Genes and Nutrition, 2018
    Co-Authors: Laars Ove Dragsted, Q. Gao, Augustin Scalbert, G. Vergeres, M. Kolehmainen, Claudine Manach, L. Brennan, L. A. Afman, D. S. Wishart, C. A. Lacueva
    Abstract:

    Biomarkers of food intake (BFIs) are a promising tool for limiting misclassification in nutrition research where more subjective dietary assessment instruments are used. They may also be used to assess compliance to dietary guidelines or to a dietary intervention. Biomarkers therefore hold promise for direct and objective measurement of food intake. However, the number of comprehensively validated Biomarkers of food intake is limited to just a few. Many new candidate Biomarkers emerge from metabolic profiling studies and from advances in food chemistry. Furthermore, candidate food intake Biomarkers may also be identified based on extensive literature reviews such as described in the guidelines for Biomarker of Food Intake Reviews (BFIRev). To systematically and critically assess the validity of candidate Biomarkers of food intake, it is necessary to outline and streamline an optimal and reproducible validation process. A consensus-based procedure was used to provide and evaluate a set of the most important criteria for systematic validation of BFIs. As a result, a validation procedure was developed including eight criteria, plausibility, dose-response, time-response, robustness, reliability, stability, analytical performance, and inter-laboratory reproducibility. The validation has a dual purpose: (1) to estimate the current level of validation of candidate Biomarkers of food intake based on an objective and systematic approach and (2) to pinpoint which additional studies are needed to provide full validation of each candidate biomarker of food intake. This position paper on biomarker of food intake validation outlines the second step of the BFIRev procedure but may also be used as such for validation of new candidate Biomarkers identified, e.g., in food metabolomic studies.

Laars Ove Dragsted - One of the best experts on this subject based on the ideXlab platform.

  • Validation of Biomarkers of food intake¿critical assessment of candidate Biomarkers
    Genes and Nutrition, 2018
    Co-Authors: Laars Ove Dragsted, Augustin Scalbert, G. Vergeres, M. Kolehmainen, Claudine Manach, L. Brennan, L. A. Afman, D. S. Wishart, C. A. Lacueva
    Abstract:

    Biomarkers of food intake (BFIs) are a promising tool for limiting misclassification in nutrition research where more subjective dietary assessment instruments are used. They may also be used to assess compliance to dietary guidelines or to a dietary intervention. Biomarkers therefore hold promise for direct and objective measurement of food intake. However, the number of comprehensively validated Biomarkers of food intake is limited to just a few. Many new candidate Biomarkers emerge from metabolic profiling studies and from advances in food chemistry. Furthermore, candidate food intake Biomarkers may also be identified based on extensive literature reviews such as described in the guidelines for Biomarker of Food Intake Reviews (BFIRev). To systematically and critically assess the validity of candidate Biomarkers of food intake, it is necessary to outline and streamline an optimal and reproducible validation process. A consensus-based procedure was used to provide and evaluate a set of the most important criteria for systematic validation of BFIs. As a result, a validation procedure was developed including eight criteria, plausibility, dose-response, time-response, robustness, reliability, stability, analytical performance, and inter-laboratory reproducibility. The validation has a dual purpose: (1) to estimate the current level of validation of candidate Biomarkers of food intake based on an objective and systematic approach and (2) to pinpoint which additional studies are needed to provide full validation of each candidate biomarker of food intake. This position paper on biomarker of food intake validation outlines the second step of the BFIRev procedure but may also be used as such for validation of new candidate Biomarkers identified, e.g., in food metabolomic studies.

  • Validation of Biomarkers of food intake-critical assessment of candidate Biomarkers
    Genes and Nutrition, 2018
    Co-Authors: Laars Ove Dragsted, Q. Gao, Augustin Scalbert, G. Vergeres, M. Kolehmainen, Claudine Manach, L. Brennan, L. A. Afman, D. S. Wishart, C. A. Lacueva
    Abstract:

    Biomarkers of food intake (BFIs) are a promising tool for limiting misclassification in nutrition research where more subjective dietary assessment instruments are used. They may also be used to assess compliance to dietary guidelines or to a dietary intervention. Biomarkers therefore hold promise for direct and objective measurement of food intake. However, the number of comprehensively validated Biomarkers of food intake is limited to just a few. Many new candidate Biomarkers emerge from metabolic profiling studies and from advances in food chemistry. Furthermore, candidate food intake Biomarkers may also be identified based on extensive literature reviews such as described in the guidelines for Biomarker of Food Intake Reviews (BFIRev). To systematically and critically assess the validity of candidate Biomarkers of food intake, it is necessary to outline and streamline an optimal and reproducible validation process. A consensus-based procedure was used to provide and evaluate a set of the most important criteria for systematic validation of BFIs. As a result, a validation procedure was developed including eight criteria, plausibility, dose-response, time-response, robustness, reliability, stability, analytical performance, and inter-laboratory reproducibility. The validation has a dual purpose: (1) to estimate the current level of validation of candidate Biomarkers of food intake based on an objective and systematic approach and (2) to pinpoint which additional studies are needed to provide full validation of each candidate biomarker of food intake. This position paper on biomarker of food intake validation outlines the second step of the BFIRev procedure but may also be used as such for validation of new candidate Biomarkers identified, e.g., in food metabolomic studies.

Rita F Redberg - One of the best experts on this subject based on the ideXlab platform.

  • Charting a roadmap for heart failure biomarker studies
    JACC: Heart Failure, 2014
    Co-Authors: Tariq Ahmad, James V. Snider, Stephan Blankenberg, Kirkwood F. Adams, Michael J Pencina, Mona Fiuzat, Nancy L Geller, Faiez Zannad, John G F Cleland, Rita F Redberg
    Abstract:

    Heart failure is a syndrome with a pathophysiological basis that can be traced to dysfunction in several interconnected molecular pathways. Identification of Biomarkers of heart failure that allow measurement of the disease on a molecular level has resulted in enthusiasm for their use in prognostication and selection of appropriate therapies. However, despiteconsiderable amounts of information available on numerous Biomarkers, inconsistent research methodologies and lack of clinical correlations have made bench-to-bedside translations rare and left the literature with countless publications of varied quality. There is a need for a systematic and collaborative approach aimed at definitively studying the clinical benefits of novel Biomarkers. In this review, on the basis of input from academia, industry, and governmental agencies, we propose a systematized approach based on adherence to specific quality measures for studies looking to augment current prediction model or use Biomarkers to tailor therapeutics. We suggest that study quality, rather than results, should determine publication and propose a system for grading biomarker studies. We outline the need for collaboration between clinical investigators and statisticians to introduce more advanced statistical methodologies into the field of Biomarkers that would allow for data from a large number of variables to be distilled into clinically actionable information. Lastly, we propose the creation of a heart failure biomarker consortium that would allow for a comprehensive list of Biomarkers to be concomitantly analyzed in a pooled sample of randomized clinical trials and hypotheses to be generated for testing in biomarker-guided trials. Such a consortium could collaborate in sharing samples to identify Biomarkers, undertake meta-analyses on completed trials, and spearhead clinical trials to test the clinical utility of new Biomarkers.

Vincent J. Gnanapragasam - One of the best experts on this subject based on the ideXlab platform.

  • The role of treatment modality on the utility of predictive tissue Biomarkers in clinical prostate cancer: a systematic review
    Journal of Cancer Research and Clinical Oncology, 2013
    Co-Authors: Naveen Kachroo, Vincent J. Gnanapragasam
    Abstract:

    Background Tissue Biomarkers could pivotally improve clinical outcome prediction following prostate cancer therapy. Clinically, prostate cancer is managed by diverse treatment modalities whose individual influence on a biomarker’s predictive ability is not well understood and poorly investigated in the literature. Objective We conducted a systematic review to assess the predictive value of Biomarkers in different treatment contexts in prostate cancer. Study methodology A literature search was performed using the MeSH headings “prostate neoplasms” and “biological markers”. Rigorous selection criteria identified studies correlating expression with clinical outcomes from primary androgen deprivation therapy (ADT), radical prostatectomy and radiotherapy (± neoadjuvant ADT). Study results Of 10,668 studies identified, 481 papers matched initial inclusion criteria. Following rescreening, 384 studies identified 236 individual tissue Biomarkers, of which 29 were predictive on multivariate analysis in at least 2 independent cohorts. The majority were only tested in surgical cohorts. Only 8 predictive Biomarkers were tested across all 3 treatments with Ki67 identified as universal predictive marker. p16 showed potential for treatment stratification between surgery and radiotherapy but needs further validation in independent studies. Conclusions Despite years of research, very few tissue Biomarkers retain predictive value in independent validation across therapy context. Currently, none have conclusive ability to help treatment selection. Future biomarker research should consider the therapy context and use uniform methodology and evaluation criteria.

Elena Colicino - One of the best experts on this subject based on the ideXlab platform.

  • DNA Methylation–Based Biomarkers of Environmental Exposures for Human Population Studies
    Current Environmental Health Reports, 2020
    Co-Authors: Jamaji C. Nwanaji-enwerem, Elena Colicino
    Abstract:

    Purpose of Review This manuscript orients the reader to the underlying motivations of environmental biomarker development for human population studies and provides the foundation for applying these novel Biomarkers in future research. In this review, we focus our attention on the DNA methylation–based Biomarkers of (i) smoking, among adults and pregnant women, (ii) lifetime cannabis use, (iii) alcohol consumption, and (iv) cumulative exposure to lead. Recent Findings Prior environmental exposures and lifestyle modulate DNA methylation levels. Exposure-related DNA methylation changes can either be persistent or reversible once the exposure is no longer present, and this combination of both persistent and reversible changes has essential value for biomarker development. Here, we present available Biomarkers representing past and cumulative exposures using individual DNA methylation profiles. Summary In the present work, we describe how the field of environmental epigenetics can leverage machine learning algorithms to develop exposure Biomarkers and reduce problems of misreporting exposures or limited access technology. We emphasize the crucial role of the individual DNA methylation profiles in those predictions, providing a summary of each biomarker, and highlighting their advantages, and limitations. Future research can cautiously leverage these DNA methylation–based Biomarkers to understand the onset and progression of diseases.